摘要
Ulinastatin(UTI),a broad-spectrum elastase inhibitor,can stabilize lysosomal membranes and inhibit the activation and release of various inflammatory cytokines caused by cardiopulmonary bypass(CPB).[1,2]UTI has recently been considered to be an effective anti-inflammatory agent and has been widely used in clinical settings,[3-5]but the optimal dose has not been defined.Therefore,we conducted a prospective,randomized,controlled trial involving 60 patients undergoing cardiac surgeries with CPB and investigated the serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-8(IL-8),at different time points in order to evaluate the antiinflammatory efficacy of high-dose UTI and explore the optimum dose.
基金
This study was supported by the grant from Science and Technology Development Plan of Yantai City(No.2015WS033).
